In 1984, K. Anji Reddy had spent two decades as a pharmaceutical chemist, synthesising active drug ingredients and understanding the science of molecules that became medicines. When he founded Dr. Reddy’s Laboratories in Hyderabad that year, he did not set out to build India’s largest pharma company or to conquer the American generic drugs market.

He set out to answer one question he had been living with for years: why should a person who cannot afford a branded drug have to take an inferior version of it?

The answer he gave, enacted operationally every single day for decades, built the foundation of what India’s pharmaceutical industry has become.

The Small Shift

Indian pharmaceutical companies in the 1980s operated in a permissive environment. Indian patent law, at the time, did not recognise product patents for drugs, only process patents. This meant that Indian manufacturers could legally reverse-engineer branded drugs and produce cheaper generic versions for domestic consumption. Most did. The incentive was clear: low R&D cost, guaranteed demand, reasonable margin.

The quality bar most Indian manufacturers applied was: sufficient to pass domestic regulatory inspection. No more.

Reddy made a different commitment. His quality standard was not ‘what the regulator requires’ but ‘what I would accept for my own family.’ The distinction sounds subtle. Operationally, it was profound.

It meant that when Indian regulators accepted a level of impurity that Reddy considered too high, his production lines held to a tighter standard anyway. It meant that when cost pressures pushed against packaging quality, excipient purity, or storage specifications, the family standard was the tiebreaker. It was not negotiable because it was personal.

This daily discipline, applied not once in a policy document but in every production decision, every quality check, every batch release, was the small shift that separated Dr. Reddy’s from its peers.

The First Export

In 1987, Dr. Reddy’s became the first Indian pharmaceutical company to export an active pharmaceutical ingredient to the United States. The drug was ibuprofen. The buyer was an American generics manufacturer. The inspection was conducted by the US Food and Drug Administration, at the time, the most exacting pharmaceutical regulator in the world.

The FDA’s inspectors found a facility that already operated to the standard they were checking for, because the internal standard had always exceeded the external one.

Three years later, in 1990, Dr. Reddy’s became the first Indian company to receive US FDA approval for a finished drug formulation, not just an ingredient, but a complete, ready-to-dispense medicine. This was a milestone that the Indian pharmaceutical industry had considered aspirational at best, unreachable at worst.

The Industry That Followed

What Dr. Reddy’s demonstrated was a proof of concept that changed the ambitions of an entire industry.

Sun Pharmaceutical, Cipla, Lupin, Aurobindo, Wockhardt, one by one, India’s pharmaceutical manufacturers began pursuing US FDA approval, European Medicines Agency clearance, and WHO pre-qualification. They invested in upgrading manufacturing facilities, quality systems, and documentation processes to meet global standards. They hired scientists trained in western regulatory environments. They built export businesses that, within two decades, made India the supplier of choice for affordable generic medicines across the developed world.

The shift that Reddy modelled, hold the standard voluntarily, before it is required, cascaded through an industry and produced outcomes that no single company could have achieved alone.

Today, India supplies over 40% of all generic drug formulations consumed in the United States and approximately 25% of all medicines dispensed in the United Kingdom’s National Health Service. More than 150 countries rely on Indian-manufactured drugs.

During the COVID-19 pandemic, when the world needed vaccines and antivirals at a scale and speed that no single country’s industry could supply, it was India’s pharmaceutical sector, built over decades on the quality discipline that Reddy pioneered, that stepped in. The Serum Institute of India alone produced more vaccine doses than any other manufacturer on earth.

Dr. Reddy’s Today

Dr. Reddy’s Laboratories today operates across more than 66 countries, employs over 24,000 people, and generates revenues exceeding ₹24,000 crore. It has over 200 US FDA-approved drug formulations and is one of the most respected generic pharmaceutical companies in the world.

K. Anji Reddy passed away in 2013. The company he founded on one daily question, would I give this to my own family?, continues to be led by the standard he set.